You are here


The Vaccination in Atherosclerosis (VIA) program is specifically focused on developing a vaccine to protect against atherosclerosis, the primary cause of cardiovascular diseases such as heart attacks and strokes


To be able to achieve this goal, we have assembled an extraordinary team of experts from academic research institutions, SMEs, and industry. Each of the partners brings unique capabilities to the program that cover the entire spectrum of activities from basic research and discovery, to initial preclinical development, advanced animal models of human diseases, clinical vaccine development, formulation science, adjuvant selection, and conducting clinical trials. This breadth and depth of expertise ensure that, as a team, the VIA program is able to bring the most promising product candidate(s) from the laboratory into the clinic and ultimately to patients with unmet needs.